RETRACTED: Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer

Sun, Chengcao; Li, Shujun; Hu, Wei; Zhang, Jian; Zhou, Qun; Li, Cong; Li, Linlin; Songyang, Yiyan; Zhang, Feng; Chen, Zhenlong; Li, Guang; Bi, Zhuoyue; Bi, Yang; Gong, Fengyun; Tao, Bo; Zhu, Yuan; Hu, Weidong; Zhan, Bo-Tao; Zhang, Qian; He, Qi-qiang; Li, Dejia

doi:10.1016/j.ymthe.2019.03.019

Cited by 137 publications

(111 citation statements)

References 50 publications

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…Deregulation of this pathway is known to be prevalent in breast cancer and is connected to poor outcome. 23 We did not find significant differences between patients with high and low RP11-19E11.1 in the prevalence of any gene alterations that can activate these pathways ( Fig. 4d, e).…”

Section: In Vitro Validation and Functional Screening Of Lncrnas Overmentioning

confidence: 67%

See 1 more Smart Citation

LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer

et al. 2020

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) play key roles in the regulation of breast cancer initiation and progression. LncRNAs are differentially expressed in breast cancer subtypes. Basal-like breast cancers are generally poorly differentiated tumors, are enriched in embryonic stem cell signatures, lack expression of estrogen receptor, progesterone receptor, and HER2 (triple-negative breast cancer), and show activation of proliferation-associated factors. We hypothesized that lncRNAs are key regulators of basal breast cancers. Using The Cancer Genome Atlas, we identified lncRNAs that are overexpressed in basal tumors compared to other breast cancer subtypes and expressed in at least 10% of patients. Remarkably, we identified lncRNAs whose expression correlated with patient prognosis. We then evaluated the function of a subset of lncRNA candidates in the oncogenic process in vitro. Here, we report the identification and characterization of the chromatin-associated lncRNA, RP11-19E11.1, which is upregulated in 40% of basal primary breast cancers. Gene set enrichment analysis in primary tumors and in cell lines uncovered a correlation between RP11-19E11.1 expression level and the E2F oncogenic pathway. We show that this lncRNA is chromatin-associated and an E2F1 target, and its expression is necessary for cancer cell proliferation and survival. Finally, we used lncRNA expression levels as a tool for drug discovery in vitro, identifying protein kinase C (PKC) as a potential therapeutic target for a subset of basal-like breast cancers. Our findings suggest that lncRNA overexpression is clinically relevant. Understanding deregulated lncRNA expression in basal-like breast cancer may lead to potential prognostic and therapeutic applications.

show abstract

Section: In Vitro Validation and Functional Screening Of Lncrnas Overmentioning

confidence: 67%

“…49 The influence of the E2F transcription factors in breast cancer development is undisputed. 23 In this study, we identified an E2F oncogenic signature in patients with upregulated RP11-19E11.1 levels. Furthermore, our results showed RP11-19E11.1 to be an E2F1 target and a chromatin-associated lncRNA.…”

Section: Discussionmentioning

confidence: 87%

LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Dysregulation of ADCY expression has been reported in various solid cancers [11,13,15,17], but the role of ADCYs in the development and progression of those cancers remains unclear, and bioinformatics analysis in AML is still lacking [20]. To explore the potential functions of ADCYs and their regulatory network in AML, we used the data published online to gain further insight into AML.…”

Section: Discussionmentioning

confidence: 99%

Prognosis and regulation of an adenylyl cyclase network in acute myeloid leukemia

Chen

Wang

et al. 2020

Aging

View full text Add to dashboard Cite

INTRODUCTION Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy [1, 2]. Three types of gene mutations are thought to play major roles in the pathogenesis of classical AML. Types I and II mutations are related to cellular proliferation and differentiation, while type III mutations affect genes encoding epigenetic factors involved in the pathogenesis and progression of AML [3]. Adenylyl cyclases (ADCYs) have been attracting increased attention in recent years [4]. These enzymes, which catalyze the generation of cAMP from ATP [5, 6], differ in their responses to upstream regulatory pathways and their distribution, and play essential roles in learning, synaptic plasticity, cardiovascular responses and tumorigenesis [7-10]. The nine members of the ADCY family (ADCY1-ADCY9) exhibit distinct responses to G protein coupled receptors and have been grouped into three subgroups based on their functional activities and sequence homology. Group 1 consists of ADCY1, ADCY3 and ADCY8, which are mainly distributed in neuronal tissues and stimulated by Ca +2 /calmodulin [10]. Group 2 contain ADCY2, ADCY4 and ADCY7, which are Ca +2-independent and are stimulated by G proteins [11]. Group 3 includes ADCY5 and ADCY6, which are mainly expressed in www.aging-us.com

show abstract

“…Will research team discovered that spliceosome was consist of ve snRNPs and numerous proteins which catalyze pre-mRNA splicing 27 . Varialbe levels of RNA and protein components in uenced splice cite and research conducted by Dvinge and their partners showed that the spliceosome shaped the global transcriptome of breast cancer 28 as potential targets of therapy 35 . The inhibition of E2F downregulated the ability of BRD4 binding with the promoter of miR-106b-5p and inhibited its transcription which resulted in the cellular senescence of gastric cancer cells were investigated by Dong, X team 36 .…”

Section: Discussionmentioning

confidence: 99%

Integrated Analysis of the Functions and Prognostic Values of RNA Binding Proteins and Candidate Drugs in Renal Papillary Cell Carcinoma

Jiang¹,

Ren²,

Liu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Roles of RNA binding proteins in renal papillary cell carcinoma (KIRP) remain undiscovered. We thus conducted a series of bioinformatics analyses to elucidate the associations between RBPs and prognosis of renal papillary cell carcinoma.Methods: RNA sequencing data and clinical of KIRP were downloaded from the TCGA database. The differentially expressed RBP coding genes (DEGs) were sorted out by R software and Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were then performed to evaluate the functional pathways. Protein-protein interaction (PPI) network of DEGs was formed through the Search Tool for the Retrieval of Interacting Genes (STRING) database and visualized by Cytoscape. Subsequently, a prognostic model was constructed by the uses of univariate Cox regression analysis, random survival forest analysis and multivariate Cox analysis. Validations of Receiver Operating Characteristic (ROC) analysis, KM analysis of overall survival and nomogram were performed as follow. Furthermore, CMap database was used to predict potential drugs.Results: A prognostic OS-predictive model based on six RBPs (SNRPN, RRS1, INTS8, RBPMS2, IGF2BP3 and PIH1D2) was constructed. STOCK1N-28457, pyrimethamine and trapidil were determined as potential drugs according to the CMap database.Conclusion: This study constructed a prognosis-related six-RBP signature and made a prediction of three small molecular drugs, which provided a novel insight into KIRP and assisted the development of individualized therapeutic strategies.

show abstract

RETRACTED: Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer

Cited by 137 publications

References 50 publications

LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer

LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer

Prognosis and regulation of an adenylyl cyclase network in acute myeloid leukemia

Integrated Analysis of the Functions and Prognostic Values of RNA Binding Proteins and Candidate Drugs in Renal Papillary Cell Carcinoma

Contact Info

Product

Resources

About